Vitamin E consists of tocopherols and tocotrienols, in which a-tocotrienol is the most potent neuroprotective form that is also effective in protecting against stroke in rodents. As neuroprotective agents alone are insufficient to protect against stroke, we sought to test the effects of tocotrienol on the cerebrovascular circulation during ischemic stroke using a preclinical model that enables fluoroscopy-guided angiography. Mongrel canines (mean weight = 26.3 ± 3.2 kg) were supplemented with tocotrienol-enriched (TE) supplement (200 mg b.i.d, n = 11) or vehicle placebo (n = 9) for 10 weeks before inducing transient middle cerebral artery (MCA) occlusion. Magnetic resonance imaging was performed 1 hour and 24 hours post reperfusion to assess stroke-induced lesion volume. Tocotrienol-enriched supplementation significantly attenuated ischemic strokeinduced lesion volume (P < 0.005). Furthermore, TE prevented loss of white matter fiber tract connectivity after stroke as evident by probabilistic tractography. Post hoc analysis of cerebral angiograms during MCA occlusion revealed that TE-supplemented canines had improved cerebrovascular collateral circulation to the ischemic MCA territory (P < 0.05). Tocotrienol-enriched supplementation induced arteriogenic tissue inhibitor of metalloprotease 1 and subsequently attenuated the activity of matrix metalloproteinase-2. Outcomes of the current preclinical trial set the stage for a clinical trial testing the effects of TE in patients who have suffered from transient ischemic attack and are therefore at a high risk for stroke.
Introduction
Of the 795,000 cases of stroke each year in the United States, B25% are repeat stroke events (Lloyd-Jones et al, 2010) . In addition, 15% of all stroke events are preceded by a transient ischemic attack (TIA), defined as a temporary episode of neurologic dysfunction caused by reduced blood flow to the brain, but without permanent damage to brain tissue (Lloyd-Jones et al, 2010) . After a TIA, the 90-day risk of stroke is as high as 17.3% (Lloyd-Jones et al, 2010) . Thus, prophylactic interventions may have a key role in favorably modifying stroke outcomes especially for those who have already suffered from a TIA, and therefore, are facing a major stroke event.
Clinical trials testing the effects of vitamin E in a wide range of major health disorders have come to the general conclusion that vitamin E either is not helpful or could be harmful under certain conditions (Lonn et al, 2005; Miller et al, 2005) . Meta-analyses of over 20 randomized, controlled clinical trials testing vitamin E have now reached conclusions that on one hand serve the basis for readjusting public policies and practices, whereas on the other suffer from a major blind spot, which is not recognized in any of these reports (Schierling et al, 2009) . Although title claims of such meta-analyses address vitamin E as whole, they fail to recognize that the only form of vitamin E studied in all these trials is a-tocopherol, which represents one-eighth of the natural vitamin E family. Natural vitamin E exists in two forms: tocopherols and tocotrienols. Both tocopherols and tocotrienols possess a chromanol ring, and within families the isoforms are differentiated as a, b, g, and d according to the presence of methyl groups at positions 5, 7, and 8, respectively. Tocopherols are characterized by a saturated side chain, whereas tocotrienols possess an isoprenoid side chain with double bonds at C-3, -7, and -11.
Recent interest in the biological properties of tocotrienol has sharply risen because of the unique biological functions of this form of natural vitamin E not shared by the better known tocopherols, which have failed to live up to expectations in clinical trials (Miller et al, 2005; Schierling et al, 2009) . At nanomolar concentrations, a-tocotrienol (aTCT) but not a-tocopherol, is a potent neuroprotective agent (Khanna et al, 2005b) . On a concentration basis, this represents the most potent of all the biological functions of the entire vitamin E family. Neural cell biology studies have identified unique aTCT-sensitive signaling checkpoints that rescue cells from inducible cell death caused by a range of insults (Sen et al, 2004) . Importantly, although aTCP is detected in serum from dietary sources, the presence of aTCT in the serum of non-supplemented Americans is negligible because of Western food habits containing trace levels of tocotrienol (Schwartz et al, 2008) . Statin-mimetic cholesterol lowering properties of aTCT in humans (Parker et al, 1993) , in addition to neuroprotection, positions them as a strong candidate for stroke therapeutics. Indeed, we have demonstrated that orally supplemented aTCT protects against stroke-induced lesion in the brain of spontaneously hypertensive rats (Khanna et al, 2005b) . As small animal studies are recognized to be of limited reliability to predict success for stroke therapeutics in clinical trials (Kidwell et al, 2001) , we developed a minimally invasive preclinical canine model (Rink et al, 2008) to test the efficacy of a tocotrienolenriched (TE) supplement in a randomized, blind, placebo (PBO)-controlled setting. Angiography, enabled in our large animal setting, helped elucidate that prophylactic TE supplementation improves collateral blood flow to the stroke-affected territory during stroke. In the clinic, angiographic collateral grading has been used as a predictor of stroke outcome (Christoforidis et al, 2005) . Molecular mechanisms of postnatal collateral growth and remodeling, termed as arteriogenesis, are distinct from those invoked in angiogenesis and vasculogenesis. Outcomes of the current work provide first evidence of a direct link between tocotrienol supplementation and the expression of pro-arteriogenic factors in perfused collaterals of the stroke-affected hemisphere.
Materials and methods
Randomized, Blind, Placebo-Controlled, Supplementation Regimen All experimentation was approved by the Institutional Animal Care and Use Committee of The Ohio
State
University. Twenty mongrel canines (2.4±0.9 yrs, 26.6±2.6 kg) were subjected to gross physical, heartworm, complete blood count, and blood chemistry tests by veterinary faculty of The Ohio State University before study inclusion. No gross physical abnormalities, heartworm, or significant differences in complete blood count or blood chemistry were observed by veterinary staff. Following baseline physicals, canines were randomized into two treatment groups-one receiving TE (n = 11, 200 mg mixed tocotrienols, Carotech, Perak, Malaysia), and the other receiving vitamin E-deficient corn oil (n = 9, vehicle PBO). Canines were maintained on standard chow (TD2025; Harlan Teklad) for the duration of the supplementation. Tocotrienol-enriched and PBO supplements were delivered orally in gel capsules that were identical in appearance and size. Canines received supplements twice per day, after morning and evening meals, for a period of 10 weeks. Stroke was induced within 12 hours after the last supplement was received. Research and veterinary staff were blinded to capsule contents and treatment groups until all magnetic resonance imaging (MRI) stroke outcome data were independently reviewed by faculty of the Center for Biostatistics at The Ohio State University Medical Center.
C-arm Fluoroscopy-Guided Preclinical Model of Acute Ischemic Stroke
The minimally invasive, endovascular approach to achieve middle cerebral artery occlusion (MCAO) in canines was performed as previously described (Rink et al, 2008) . Briefly, the anesthetized canine (1.5% to 2.0% isoflurane) underwent bilateral femoral artery access with five French sheaths (ArrowGE Healthsystems, Waukesha, WI, USA) from which 4-Fr and 5-Fr guide catheters (Boston Scientific, Natick, MA, USA) were used to provide access to the basilar artery system and for routine contrast (Omnipaque) visualization of the middle cerebral artery (MCA) territories. Microcatheter techniques were used to access and occlude the MCA from the basilar artery. An embolic coil (3 mm Â 20 cm Ultrasoft Matrix2 Platinum Coil, Boston Scientific) was delivered into the M1 segment of either MCA from a microcatheter (SL-10, Boston Scientific), and occlusion was documented using digital subtraction angiograms of the internal carotid and vertebrobasilar circulation every 15 minutes throughout the 1 hour occlusion period. Following 1 hour of MCAO, the embolic coil was retrieved and digital subtraction angiograms used to confirm reperfusion. Angiographic documentation of vessel perforation and hemorrhage was grounds for study exclusion. Physiologic parameters were monitored throughout the procedure, and included blood pressure and blood parameters determined before MCAO, during occlusion, and after reperfusion. Following reperfusion, endovascular devices were withdrawn and arteriotomy sites closed. Under veterinary care, canines were immediately transported to the Wright Center of Innovation at The Ohio State University for 1 hour post reperfusion MRI. Fluoroscopy-guided angiograms documenting the surgical procedure are provided in Supplementary Figure S1 .
Magnetic Resonance Imaging
Evaluation of the infarct volume was performed using an 8-channel sensitivity encoding (SENSE) knee coil in a 3T MRI (Achieva, Philips Healthcare, Andover, MA, USA) MRI imaging system. Images were obtained at 1 hour and 24 hours following reperfusion. Sequences included: diffusion tensor imaging (DTI; field of view (FOV) = 140 Â 140 mm 2 , matrix = 128 Â 128, number of excitations (NEX) = 1, repetition time (TR)/echo time (TE) 192-2131/71, Slice thickness = 3 mm, b value = 1,000, total scan time B4 minutes) and T2 fluid attenuated inversion recovery (FLAIR; FOV = 160 mm, matrix = 512 Â 512, NEX = 1, TR/TE/TI (inversion time) = 11,000/125/ 2,800, slice thickness = 3 mm, total scan time B8 minutes) and three-dimensional time-of-flight magnetic resonance angiography (FOV = 150 mm, matrix = 512 Â 512, TR/TE = 8.6/3.45, flip angle = 20, slice thickness = 1 mm, total scan time B6 minutes). Diffusion tensor imaging data were transferred to a workstation where mean diffusivity maps were derived from the 1 hour post reperfusion DTI (FSL 4.1.4, Oxford University, Oxford, UK). Magnetic resonance angiography reconfirmed reperfusion to the transiently occluded territory. Infarct volumes were calculated by importing mean diffusivity maps and FLAIR images into Image J (National Institutes of Health). Two blinded observers independently outlined infarct volumes using a semi-automated threshold technique as previously described (Christoforidis et al, 2011) .
Streamline and Probabilistic White Matter Fiber Tracking
Streamline tractography of the internal capsule was performed using the FACT algorithm with Trackvis software (ver. 0.5.1). Probabilistic tractography (Behrens et al, 2003) enables quantitative analysis of DTI-based connectivity as opposed to the streamline tractography. To investigate the therapeutic efficacy of TE to protect white matter connectivity after stroke, a probabilistic tractography framework was employed using the FSL software package (Smith et al, 2004) . Our probabilistic approached used a single regions of interest (ROI) mask with 10,000 tracts cast from each voxel in the internal capsule ROI (curvature threshold of 0.2). The connectivity images resided in their native space and were not directly comparable. For this reason, tensor images for each sample, for each timestamp, were fed into a tensor field-based elastic registration routine to compute a population average tensor image and the transformations that mapped each data onto this average brain space. This registration was performed using DTI-TK toolkit (ver. 2.0).
Transformations were applied to the corresponding tract images in the same coordinate framework, that of the mean tensor image.
Angiographic Evaluation of Cerebrovascular Collateral Recruitment
Digital subtraction angiogram acquisitions obtained just before reperfusion were reviewed to assess cerebrovascular collateral recruitment using an 11point scale, as previously described (Christoforidis et al, 2011) . This scale takes into account the anatomic extent and transit time of leptomeningeal collaterals from the posterior and anterior cerebral artery circulations to the affected MCA territory. Digital subtraction angiogram images were reviewed to identify leptomeningeal collateral reconstitution of the anterior, middle, and posterior aspects of the MCA territory. The horizontal portions of the MCA and posterior cerebral artery were used as landmarks dividing the MCA territory into these three regionsanterior, middle, and posterior. Images were compared with the arterial and venous phases of the preocclusion arteriograms on the side of the occlusion.
Vitamin E Extraction and Analysis
Vitamin E extraction and analysis of canine brain tissue was performed as previously described using an HPLC-coulometric electrode array detector (Coularray Detector, 12-channel, model 5600, ESA, Chelmsford, MA, USA). This system enables the simultaneous detection of all eight naturally occurring vitamin E family members in a single run (Roy et al, 2002) .
Laser Microdissection Pressure Catapulting
Following 24 hour MRI, canines were euthanized and brain tissue collected for downstream applications, including laser microdissection pressure catapulting. Continuous coronal slices (3 mm) of canine brain, which include the M1 segment of the MCA were embedded and frozen in OCT compound (Sakura). Embedded brains were sliced into 12 mm thick sections using a cryostat (CM3050 s, Leica Microsystems, Buffalo Grove, IL, USA). Sections were mounted onto RNAse inhibitor-treated thermoplastic (polyethylene napthalate)-covered glass slides (PALM Technologies, Bernried, Germany). Slides were incubated in RNA-later stabilization reagent (Applied Biosystems, Carlsbad, CA, USA) for 4 minutes and quick-stained with anti-VWF antibody (1:50 dilution, 15 minutes) for selective capture of endothelial cells from stroke-affected (ipsilateral) and contralateral control tissue. More than 800,000 mm 2 of capture elements were collected for downstream RNA isolation, cDNA synthesis and real-time PCR. For high-throughput collection, all elements were captured using a PALM MicroLaser, MicroBeam, and RoboStage/RoboMover system. RNA was isolated from captured and catapulted elements using the PicoPure RNA Isolation Kit (Arcturus, Carlsbad, CA, USA) as described .
Real-Time PCR
Expression levels of collateral gene candidates were independently determined at 24 hours from contralateral control and stroke-affected laser microdissection pressure catapulting-captured elements using real-time PCR, as previously described . Briefly, total RNA ( > 250 ng) was reverse transcribed into cDNA using oligo-dT primer and Superscript III. Reverse transcriptase-generated DNA was quantified by real-time PCR assay using doublestranded DNA-binding dye SYBR Green-I. Relative gene expression was standardized to 18s rRNA. Data are shown as mean±s.d. Primer sequences are provided in the Online Supplementary Table S1 .
Western Blot Analysis
To extract protein from the canine brain, S1 cortex and contralateral control tissue was homogenized on ice in lysis buffer (50 mmol/l Tris-HCL pH 7.6; 1.5 mmol/L NaCl; 0.5 mmol/L CaCl2; 0.01% Brij 35; 1% Triton X-100) and centrifuged at 41C for 15 minutes at 14,000 g. Protein expression of matrix metalloproteinase-2 (MMP2) in canine cortex was determined by western blot analysis as previously described (Khanna et al, 2005b) using MMP2 antibody (Enzo Life Sciences, Plymouth Meeting, PA, USA). Proteins were separated on 4% to 12% gels (Invitrogen, Carlsbad, CA, USA) by SDS-PAGE, transferred onto polyvinylidene difluoride membranes, and membranes were incubated with Tris-buffered saline (TBS) containing 5% milk for 12 to 18 hours at 41C with MMP2 antibody (1:400 dilution). Next, membranes were washed three times with TBS containing 0.1% Tween-20 (TBS Tween-20) and incubated for 1 hour at room temperature in horseradish peroxidase-conjugated secondary donkey anti-rabbit antibody (GE Healthcare Life Sciences, Waukesha, WI, USA, 1:2,000 dilution in TBS Tween-20 containing 5% milk). Immunoblots were developed with ECL PlusTM Western blotting Detection Reagents (GE Healthcare Life Sciences) according to manufacturer's recommendation. To evaluate the loading efficiency, the membranes were probed with anti-b-actin antibody (Sigma-Aldrich, St Louis, MO, USA, 1:5,000, in TBS, 1 hour). Each western blot was scanned and analyzed using National Institutes of Health ImageJ software (ver. 1.44) for the density of the bands.
Gelatin Zymography
Matrix metalloproteinase-2 activity was determined by gelatin zymography as described (Beceriklisoy et al, 2007) . Briefly, 50 mg total protein were com-bined in a 1:1 ratio with Tris-glycerine SDS-loading buffer (Invitrogen) and samples were separated through electrophoresis on 10% polyacrylamide gels containing 0.1% gelatin (Invitrogen). Gels were incubated in renaturing buffer (Invitrogen) for 30 minutes, and then treated in developing buffer (Invitrogen) for 30 minutes. Gels were incubated for 24 hours at 371C in fresh developing buffer with gentle agitation. Gels were stained with 20 ml of SimplyBlue SafeStain (Invitrogen), destained, and imaged using Pharos FX plus molecular imager (Bio-Rad, Hercules, CA, USA) and analyzed using National Institutes of Health ImageJ software (ver. 1.44) for the density of the bands.
Statistical Analysis
Statistically treated data are reported as mean ± SD. Difference between means was tested with Student's t-test or one-way ANOVA with Tukey's post hoc test where appropriate (alpha level = 0.05). SPSS software (v17.0, IBM, Somers, NY, USA) was used for all statistical calculations.
Results

Oral TE Supplementation Attenuates Stroke-Induced Lesion Volume and Edema
Healthy mongrel canines were randomized to treatment groups and orally administered 200 mg TE (containing 61.52 mg aTCT, 112.8 mg g-tocotrienol, and 25.68 mg d-tocotrienol; n = 11) or vehicle control (PBO containing vitamin E stripped corn oil, n = 9) gel capsules twice daily for 10 weeks before experimental stroke. Randomization was supervised by the trial statistician, while research and veterinary personnel were blinded to supplement content and experimental groups until the conclusion of the study. Tocotrienol-enriched supplementation had no significant effect on monitored physiologic parameters before (baseline), during, or immediately after stroke reperfusion (Table 1) . Oral TE capsule supplementation significantly increased the concentration of tocotrienols in MCA supplied cerebral cortex as compared with PBO controls ( Figure 1A ). Tocotrienolenriched supplementation enriched cortical brain tissue with nearly equal amounts of aand gtocotrienol isoforms (77.4 nmol/g protein and 77.5 nmol/g protein, respectively) and approximately one-third that amount of d-tocotrienol isoform (22.4 nmol/g protein). Like Western diet, canine chow is deficient in tocotrienols. No appreciable amount of a-, g-, or d-tocotrienol was detected in cortex of PBO controls despite using a highly-sensitive electrochemical HPLC approach (Roy et al, 2002) . The concentration of aand gtocotrienol in TE-supplemented animals was 10-fold less than that of a-tocopherol found in cerebral cortex ( Figure 1B) . Tocotrienol-enriched supplementation, representing a blend of natural vitamin E enriched from palm oil, modestly increased the concentration of a-tocopherol in brain tissue as compared with PBO controls; whereas no difference in g-tocopherol concentration was observed between PBO and TE groups.
Cytotoxic edema is characterized by cellular swelling in the acute phase ( < 24 hours) of stroke onset. Cerebral ischemia in hyper-metabolic brain tissue causes failure of ATP-dependent ion transporters, resulting in rapid accumulation of intracellular Na 2 + and an influx of water to maintain osmotic equilibrium. Diffusion tensor imaging enables early detection of cytotoxic edema after acute ischemic stroke. Mean diffusivity maps generated from DTI revealed that TE-supplemented canines had significantly attenuated (P < 0.05) cytotoxic edema at 1 hour following acute ischemic stroke as compared with PBO controls (Figures 1C and 1D) . Although strokeinduced lesion volume more than doubled in PBO canines between the 1 hour and 24 hours (9804.7to 20579.8 mm 3 ) time points after reperfusion, lesion volume in TE-supplemented canines remained consistently low (3675.3 to 3834.9 mm 3 , Figures 1C and 1E) . At 1 hour time point, stroke-induced lesion volume of TE-supplemented canines was < 40% that of PBO controls; and at 24 hours TE infarct volume was < 20% of their PBO counterparts. Three-dimensional volumetric reconstruction of brain from representative PBO and TE FLAIR images at 24 hours provides a clear visual appreciation of the protective effects of TE supplementation (Supplementary Figure S2) .
White Matter Fiber Tract Connectivity is Protected In TE-Supplemented Canines after Stroke
White matter fiber pathways represent the brain's communication network. The cytoarchitecture and anatomical connectivity of cerebral white matter with cerebral cortex (gray matter) directly influences brain function (Passingham et al, 2002) . White matter injury in the context of stroke has a direct effect on sensorimotor impairment and post-stroke functional recovery (Schaechter et al, 2008) . In brain tissue that possesses a high degree of directional organization, the diffusion of water and its protons aligns with the orientation of white matter fiber tracts. Recent developments in DTI have enabled visualization of white matter fiber tract connectivity after stroke. Fiber tract projections from the region of the internal capsule to the corona radiata were dramatically reorganized in PBO canine brain 24 hours after stroke reperfusion (Figure 2A, Supplementary Figure S3 ). Specifically, streamline tractography visualization of fiber tracts revealed impaired connectivity between ROI set in the internal capsule and corona radiata. Oral TE supplementation protected fiber tract projections in the stroke-affected hemisphere as compared with PBO control. Probabilistic tractography is a powerful tool for quantitative analysis of white matter connectivity (Behrens et al, 2003) . We used a probabilistic tractography framework to quantitatively assess the effect of TE supplementation on BPM, beats per minute; MCA, middle cerebral artery; MCAO, middle cerebral artery occlusion; PBO, placebo; TCT, tocotrienol. Canine physiological parameters were assessed at baseline (before embolic occlusion of the MCA), during ischemia, and immediately following reperfusion.
Tocotrienol protects against ischemic stroke C Rink et al white matter fiber tract connectivity in strokeaffected cortex. To quantitatively assess connectivity, 40,000 tracts were cast from voxels in the internal capsule ROI to the distal corona radiata ROI ( Figure  2B ). Relative connectivity of fiber tracts between the internal capsule and corona radiata was much higher in representative TE-supplemented canine brain as compared with PBO control. The PBO canine brain had a higher tract variance as a function of distance from the internal capsule seed ROI as compared with the TE counterpart ( Figure 2C ).
TE Supplementation Improved Cerebrovascular Collateral Circulation During Ischemic Stroke
Collateral arteries of the leptomeningeal space anastomose across border zones of cortical water- sheds in humans and large mammals alike underscoring the translational significance of our approach. This arterial network facilitates an alternative means to circulate blood, via retrograde filling, to tissue in instances when injury or occlusion to primary cortical branches disrupts cerebrovascular blood flow. Improving collateral circulation and blood perfusion to the stroke-affected territory is a therapeutic target of recognized value in the clinic (Brozici et al, 2003) . In many cases, a focal circulatory abnormality created by arterial occlusion can be adequately compensated through cerebrovascular collateral circulation. Our preclinical canine stroke model benefits from angiographic assessment of collateral circulation during MCAO (Christoforidis et al, 2011; Rink et al, 2008) . Post hoc analysis of cerebral angiograms during ischemic stroke revealed that canines receiving oral TE supplementation had improved cerebrovascular collateral circulation as compared with PBO controls (Figure 3) . Pre-and post-MCAO internal carotid artery angiograms (Figures 3A -J) enable objective scoring of stroke-affected hemisphere collaterals according to a clinically relevant 11-point scale. Middle cerebral arteryterritory collateral score was significantly higher in TE-supplemented canines as compared with PBO controls (PBO = 5.2±1.9, TE = 8.1±2.9; Figure 3K) . A higher collateral score, and therefore better perfusion in the stroke-affected hemisphere, tightly correlated with smaller stroke-induced lesion size at 24 hours (r 2 = 0.821, Figure 3L ).
Tocotrienol-Enriched Supplement Induced Expression of Arteriogenic Genes in Cerebral Cortex Collaterals
Arteriogenesis refers to a positive outward remodeling of pre-existing collateral arteries into larger vessels, which bypass sites of occlusion (Buschmann and Schaper 2000; Hillmeister et al, 2008) . To determine whether TE supplementation invoked molecular mechanisms of cerebral arteriogenesis, arterioles from the stroke-affected (ipsilateral) and contralateral control cerebral cortex were selectively isolated laser microdissection pressure catapulting ( Figures 4A-D) . Known gene targets of cerebral arteriogenesis include members of the chloride intracellular channel, tissue inhibitor of metalloprotease 1 (TIMP1), and vascular endothelial growth factor (Chalothorn et al, 2007; Chalothorn et al, 2009; Hillmeister et al, 2008) . Increased gene expression of chloride intracellular channel 1 and TIMP1 was observed in stroke-affected cortex of TE-supplemented canines as compared with PBO controls ( Figures  4E and 4G) . Of particular note, TE supplementationdependent increase in TIMP1 expression was not limited to stroke-affected endothelial cells at the ipsilateral site. Tocotrienol-enriched supplementation induced TIMP1 in arterioles captured from contralateral control tissue ( Figure 4G) . These effects were specific as other arteriogenic candidate genes such as chloride intracellular channel 4 and vascular endothelial growth factor were not affected by TE supplementation (Figures 4F and 4H) . Tissue inhibitor of metalloprotease 1 binds to active MMP2 in a 1:1 stoichiometric ratio, providing localized control of MMP activity. Independent of MMP2 protein expression ( Figures 5A and 5B) , TE supplementation significantly attenuated MMP2 activity in the strokeaffected cerebral cortex ( Figures 5C and 5D ).
Discussion
Emblematic of the high morbidity and mortality associated with stroke are the failures of potential stroke therapeutics, which showed benefit in small animal rodent stroke models but failed to translate into clinical success (Kidwell et al, 2001) . As a result, rodent stroke models have been criticized for the anatomical disparity between small and large mammalian brains, large variability in infarct volumes, and inaccurate methods of inducing and confirming arterial occlusion (Gerriets et al, 2004) . These considerations develop a compelling rationale to engage a translational relevant preclinical approach to test the therapeutic efficacy of TE natural vitamin E (Rink et al, 2008) . As compared with the lissencephalic brain of rodents, the size and anatomical feature set of the canine brain closely mimics that of humans. Canines have a highly evolved gyrencephalic neocortex with a white to gray matter ratio that closely approximates primates, and like humans, collateral circulation in the MCA territory has been documented in canines (Symon, 1960) . Furthermore, the current experimental model benefits from C-arm fluoroscopy visualization of MCAO. As opposed to the widely used rodent intraluminal thread model of MCAO, this method permits repeated real-time documentation of the stroke event, improving the overall reproducibility of the procedure and enabling objective assessment of collateral circulation during cerebral ischemia (Christoforidis et al, 2011) . In this work, the latter proved to be pivotal in identifying the effects of TE on perfusion of the stroke-affected brain tissue. This observation, enabled by the translational approach adopted, was the first to elucidate the cerebrovascular effects of tocotrienol. Until this point, the current literature documents significant protective effects of stroke in vivo but explains it exclusively on the basis of TE's neuroprotective properties. a-Tocotrienol-specific mechanisms of neuroprotection depend on three key cytosolic targets involved in glutamate excitotoxicity and neurodegeneration: c-Src kinase, 12-lipoxygenase, and phospholipase A 2 (Khanna et al, 2005b; Khanna et al, 2010; Sen et al, 2000) . Neuroprotectants alone, however, are thought to be insufficient in providing meaningful protection against stroke (Rogalewski et al, 2006) . Multimodal therapies that target both neuro and vascular pathophysiology are desirable. This work is the first to demonstrate a prophylactic intervention to improve collateral circulation during acute ischemic stroke. The favorable effects of TE on collateral perfusion of the stroke site taken together with its known neuroprotective properties provide two powerful mechanisms that support the case for TE in stroke therapeutics.
The cerebrovascular collateral circulation refers to a subsidiary network of small vascular channels that can stabilize cerebral blood flow when principal conduits are obstructed, as in ischemic stroke (Liebeskind, 2005) . These small collateral pathways can occur through leptomeningeal arterioles that overlap and anastomose distal branches of the anterior and posterior cerebral arteries with the MCA. Indeed, the risk and severity of strokemediated pathology is worse in patients with poor collateral circulation (Christoforidis et al, 2005) . The mechanistic process in which pre-existing arterioles are recruited to bypass the site of occlusion is termed arteriogenesis. Arteriogenesis invokes a rapid proliferative and remodeling response that is distinct from passive dilatation, developmental vasculogenesis, or neovascular angiogenesis (Buschmann and Schaper, 1999) . Induction of arteriogenic collateral growth in the brain occurs as early as 24 hours following vessel occlusion (Schierling et al, 2009) and the onset of adaptive arteriogenesis is marked by early-phase expression of protease inhibitor TIMP1 in growing collaterals of the brain (Hillmeister et al, 2008) . In this work, TE supplementation significantly increased TIMP1 expression in both contralateral control and stroke-affected arterioles of the cerebral cortex. The observation that TE induces TIMP1 expression in the blood vessel of contralateral hemisphere points to the hypothesis that long-term orally supplemented TE may prime the cerebral vasculature, enabling adaptive arteriogenesis in response to focal cerebral ischemia. Indeed, controlling extracellular matrix degradation and advancing vascular remodeling by the activation of cell proliferation represents an important role of TIMP1 in arteriogenesis (Hillmeister et al, 2008) . This work provides first evidence of TE supplementation regulating TIMP1 expression and subsequently invoking cerebrovascular arteriogenesis. It is reported that the tocotrienol-rich fraction of palm oil improves endothelium-dependent relaxation in isolated aortic rings of diabetic and hypertensive rats (Muharis et al, 2010) . Thus, in addition to the pro-arteriogenic property TE may improve cerebrovascular circulation at the stroke site by inducing arterial dilatation. DTI enables repeated, non-invasive assessment of white matter cytoarchitecture and connectivity due to unrestricted parallel (anisotropic) diffusion of water molecules along axonal fiber tracts. This MRI-based technique has emerged as a clinically relevant tool for the prognostic diagnosis of neurologic deficit and assessment of rehabilitation potential in stroke patients (Kunimatsu et al, 2003) . Proceeding from the cortex, white matter fiber tracts of the corona radiata, or 'radiating crown', converge and pass between the lenticular nucleus and thalamus in the form of a band called the internal capsule. The fiber tracts of the corona radiata and internal capsule contain corticospinal nerve bundles that are responsible for sensorimotor neurotransmission between somatosensory cortex and motor neurons (Higano et al, 2001) . This work used streamline and probabilistic tractography to assess stroke-mediated injury and loss of white matter connectivity between internal capsule and the corona radiata after stroke. White matter of TE-treated animals, not PBO, maintained the cytoarchitectural connection between internal capsule and corona radiata, suggesting that TE protected anatomical connectivity, and therefore biological function, from stroke injury. Taken together with the marked improvement in functional outcomes following MCAO in TE-supplemented mice, data strongly suggest that prophylactic TE supplementation attenuates the severity of strokeassociated sensorimotor injury.
In addition to tractography, DTI also enables assessment of stroke-induced lesion. During the acute phase of cerebral ischemia (0 to 24 hours post reperfusion), a decline in apparent diffusion coefficient maps generated from DTI is associated with cytotoxic edema causing irreversible brain injury (Ducreux et al, 2001) . Using DTI imaging immediately after stroke reperfusion, we found that TE supplementation attenuated stroke-induced cytotoxic edema within the first hour following reperfusion. Although cytotoxic edema evolves over minutes to hours, vasogenic edema occurs over hours to days and is associated with blood-brain barrier disruption (Heo et al, 2005) . Magnetic resonance imaging performed at 24 hours used a T2-weighted FLAIR sequence that captures both cytotoxic and vasogenic components of stroke-induced edema. Lesion volume in TE-supplemented animals did not significantly increase between 1 and 24 hours MRI, suggesting that TE largely prevented blood brain barrier disruption and subsequent vasogenic edema.
As a nutrient tocotrienols have been safely consumed by humans, especially in the Far East, for many years. Furthermore, tocotrienols have been Generally Recognized As Safe (GRN No. 307) certified by the US FDA as ingredients in food. In nature, tocopherols and tocotrienols are found in abundance throughout the plant kingdom. Tocopherols are the primary source of vitamin E in photosynthetic plant tissue, whereas tocotrienols are enriched in endosperm of cereals, grains, and palm seed . A growing body of studies support that different members of the natural vitamin E family may have unique biological properties relevant to health and disease (Aggarwal et al, 2010) . For example, anti-tumorigenic properties of g-tocotrienol, not shared by a-tocopherol, have been described in both breast (Park et al, 2010) and prostate (Kumar et al, 2006) cancer. Furthermore, tocotrienol transport to tissue, including brain, has been reported in the absence of tocopherol transfer protein (TTP), the transport system with high affinity for a-tocopherol (Khanna et al, 2005a) . Indeed, loss of fertility in TTP À/À mice could be rescued by TE supplementation (Khanna et al, 2005a) . At a time when meta-analyses of clinical trials testing the effect of tocopherols in a variety of disease setting draw major conclusions relevant to public health policies and practices, this work illuminates a blind spot reminding that title claims on vitamin E should be limited to the specific form of vitamin E studied.
This work demonstrates that prophylactic supplementation of natural vitamin E tocotrienols reduces brain injury after stroke in a preclinical setting. Given the observed effect of TE in improving collateral circulation during cerebral ischemia and the established hypo-cholesterolemic effects of tocotrienol supplementation (Parker et al, 1993) , the current work lays the foundation to test the effects of prophylactic TE supplementation on reducing stroke incidence. Outcomes of the current study clearly support clinical assessment of TE in a high-risk stroke population, such as TIA patients. With more than 200,000 Americans each year, the TIA patient population is well suited for testing the efficacy of TE in a clinical trial setting.
